UCP RAPID DRUG SCREENING BUPRENORPHINE, AMP 300, MAMP 500, COC 150 TEST;

K091612 · Ucp Biosciences, Inc. · DJG · Feb 24, 2010 · Clinical Toxicology

Device Facts

• Record ID: K091612
• Device Name: UCP RAPID DRUG SCREENING BUPRENORPHINE, AMP 300, MAMP 500, COC 150 TEST
• Applicant: Ucp Biosciences, Inc.
• Product Code: DJG · Clinical Toxicology
• Decision Date: Feb 24, 2010
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3650
• Device Class: Class 2

Indications for Use

UCP Drug Screening Buprenorphine, Amphetamine 300, Methamphetamine 500, Cocaine 150 Tests are rapid, qualitative, competitive binding immunoassays and intended for qualitatively the detection of Buprenorphine, Amphetamine, Methamphetamine, Cocaine and their metabolites in human urine at the following cut-off concentrations: Buprenorphine 10 ng/mL, Amphetamine 300 ng/mL, Methamphetamine 500 ng/mL, Cocaine 150 ng/mL. The tests provide only preliminary test results, which should be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to be used in monitoring the drugs levels. For professional use only For In Vitro Diagnostics only

Device Story

UCP Rapid Drug Screening tests are lateral flow immunoassays for qualitative detection of buprenorphine, amphetamine, methamphetamine, and cocaine in human urine. Device formats include dipstick, cassette, and test cup. Principle of operation: competitive binding immunoassay; urine sample migrates via capillary action through membrane; drug in sample competes with immobilized drug conjugate for limited anti-drug antibodies labeled with colloidal gold. If drug concentration is below cutoff, anti-drug antibodies bind to immobilized drug antigen, forming visible test line (negative result). If drug concentration is at or above cutoff, no test line forms (preliminary positive). Control line confirms proper sample flow. Used in point-of-care settings by healthcare professionals. Results are visually read. Preliminary positive results require confirmation via GC/MS or LC/MS. Device aids in clinical decision-making regarding drug use.

Clinical Evidence

No clinical studies were performed. Performance was evaluated via method comparison study using 80 unaltered clinical urine samples per drug, compared against GC/MS or LC/MS/MS reference methods. Results demonstrated agreement between the candidate device and the reference method across all three formats (dip card, cassette, cup). Analytical performance (precision, cross-reactivity, interference) was established through bench testing using spiked urine samples.

Technological Characteristics

Lateral flow immunochromatographic assay; competitive binding format. Form factors include test strip, test device, and test cup. Standalone, non-instrumented, visual readout. In vitro diagnostic use.

Indications for Use

Indicated for the qualitative detection of Buprenorphine, Amphetamine, Methamphetamine, Cocaine, and their metabolites in human urine at specified cut-off concentrations. Intended for professional in vitro diagnostic use. Not for monitoring drug levels. Preliminary results require confirmation by GC/MS or LC/MS.

Regulatory Classification

Identification

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• ACON BUP One Step Buprenorphine Test Strip
• ACON BUP One Step Buprenorphine Test Device
• ACON AMP-300 One Step Amphetamine Test Strip
• ACON AMP-300 One Step Amphetamine Test Device
• ACON mAMP-500 One Step Methamphetamine Test Strip
• ACON mAMP-500 One Step Methamphetamine Test Device
• ACON COC-150 One Step Cocaine Test Strip
• ACON COC-150 One Step Cocaine Test Device

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k091612

B. Purpose for Submission:
New device

C. Measurand:
Amphetamine, Buprenorphine, Cocaine and Methamphetamine

D. Type of Test:
Qualitatively, immunochromatographic assay

E. Applicant:
UPC BioSciences, Inc.

F. Proprietary and Established Names:
UCP Rapid™ Drug Screening BUP, AMP 300, mAMP 500 and Cocaine 150 Tests

G. Regulatory Information:

| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DJG | Class II | 21 CFR 862.3650, Opiate test system | 91- Toxicology |
| DKZ | Class II | 21 CFR 862.3100, Amphetamine test system | 91- Toxicology |
| LAF | Class II | 21 CFR 862.3610, Methamphetamine test system | 91-Toxicology |
| DIO | Class II | 21 CFR 862.3250, Cocaine and cocaine metabolite test system | 91-Toxicology |

{1}

H. Intended Use:

1. Intended use(s):

See the Indications for Use below

2. Indication(s) for use:

The UCP Drug Screening Buprenorphine, Amphetamine 300, Methaphetamine 500, Cocaine 150 Tests are rapid, qualitative, competitive binding immunoassays for the detection the following drug in human urine:

| Test | Calibrator | Cut-off |
| --- | --- | --- |
| Buprenorphine | Buprenorphine | 10 ng/mL |
| Amphetamine | D-Amphetamine | 300 ng/mL |
| Methamphetamine | D-Methamphetamine | 500 ng/mL |
| Cocaine | Benzoylecgonine | 150 ng/mL |

The tests contain three formats: 1) Test Card/Strip, 2) Test Device, 3) Test Cup. The test configuration comes with single drug screening test or any combinations of multiple drug screening tests. The test is intended for in vitro diagnostics use.

This assay provides only preliminary results. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) or Liquid chromatography/mass spectrometry (LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

3. Special conditions for use statement(s):

The device is for in vitro diagnostic prescription use.

This device is indicated for use in point-of-care settings.

This assay provides only preliminary results. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) or Liquid chromatography/mass spectrometry (LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

4. Special instrument requirements:

Not applicable, as the device is a visually-read single-use device.

{2}

I. Device Description:

The UCP Drug Screening Amphetamine, Buprenorphine, Cocaine and Methamphetamine are test strips contained within the following formats; dipstick (dip card), cassette (test device) and test cup. Each device can contain from 1 to 4 drug test strips. The strips contain a membrane coated with drug-protein conjugates (purified bovine albumin) on the T zone, goat polyclonal antibody against gold-protein conjugate at the C zone and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibodies specific against the drug being tested.

Controls are recommended but not provided

J. Substantial Equivalence Information:

1. Predicate device name(s):

ACON BUP One Step Buprenorphine Test Strip
ACON BUP One Step Buprenorphine Test Device

ACON AMP-300 One Step Amphetamine Test Strip
ACON AMP-300 One Step Amphetamine Test Device

ACON mAMP-500 One Step Methamphetamine Test Strip
ACON mAMP-500 One Step Methamphetamine Test Device

ACON COC-150 One Step Cocaine Test Strip
ACON COC-150 One Step Cocaine Test Device

2. Predicate K number(s):

K033299, k060466, k041822 and k032903 respectively

{3}

4

3. Comparison with predicate:

| Item
Intended use | Similarities/Differences | |
| --- | --- | --- |
| | Device
Is a lateral flow chromatographic immunoassay designed to qualitatively detect the presence of drug(s) and/or drug metabolites in human urine. | Predicate
Same |
| Sample matrix | Urine | Same |
| Analytes | Amphetamines, Burenorphine, Cocaine, Methamphetamine, | Same |
| Cutoffs | BUP 10, AMP 300, mAMP 500 and COC 150 | Same |

K. Standard/Guidance Document Referenced (if applicable):

None were identified.

L. Test Principle:

UCP Drug Screening devices are a one-step lateral flow immunoassay containing a purple-colored conjugate pad with colloidal gold conjugate with anti-drug antibodies, a nitrocellulose membrane with a test line (T) and a control line (C). The T line is coated with the drug antigen and the C line is coated with goat anti-mouse IgG antibodies. The test is a competitive binding immunoassay in which drugs and drug metabolites in a urine sample compete with immobilized drug conjugate for limited labeled antibody binding sites. When a sufficient amount of sample is applied the sample migrates through the test device by capillary action. If the concentration of drug is below the cutoff level, the anti-drug antibodies in the colloidal gold particles will bind to the drug antigens coated in the test zone producing a band which indicates a negative result. If the drug concentration is at the cutoff level or higher no band will form in the test zone indicating a preliminary positive. A band should form in the control region regardless of the presence of drug or drug metabolite in the sample.

{4}

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Reproducibility was evaluated by spiking drug free negative urine to the following concentrations (Negative, 50%, 75%, 125%, 150% and 200% of the cutoff) for each analyte. Testing was performed at three Point-of-Care sites three operators/site each testing one of three formats. Each sample, at each concentrations of each drug, was blind labeled and tested 1 to 2 times a day, for 10 non-consecutive days. A total of 30 determinations, at each concentration, were made. Results are presented in the tables below:

Amphetamine cutoff 300 ng/mL

| Drug Concentration (ng/mL) | % of cutoff | Total number of Determinations | Dip Card results #Neg/#Pos | Cassette results #Neg/#Pos | Cup results #Neg/#Pos |
| --- | --- | --- | --- | --- | --- |
| 0 | Negative | 30 | 30/0 | 30/0 | 30/0 |
| 150 | 50% | 30 | 30/0 | 30/0 | 30/0 |
| 225 | 75% | 30 | 20/10 | 19/11 | 18/12 |
| 375 | 125% | 30 | 11/19 | 12/18 | 13/17 |
| 450 | 150% | 30 | 0/30 | 0/30 | 0/30 |
| 600 | 200% | 30 | 0/30 | 0/30 | 0/30 |

Methamphetamine cutoff 500 ng/mL

| Drug Concentration (ng/mL) | % of cutoff | Total number of Determinations | Dip Card results #Neg/#Pos | Cassette results #Neg/#Pos | Cup results #Neg/#Pos |
| --- | --- | --- | --- | --- | --- |
| 0 | Negative | 30 | 30/0 | 30/0 | 30/0 |
| 250 | 50% | 30 | 30/0 | 30/0 | 30/0 |
| 375 | 75% | 30 | 18/12 | 19/11 | 18/12 |
| 625 | 125% | 30 | 11/19 | 13/17 | 11/19 |
| 750 | 150% | 30 | 0/30 | 0/30 | 0/30 |
| 1000 | 200% | 30 | 0/30 | 0/30 | 0/30 |

Cocaine cutoff 150 ng/mL

| Drug Concentration (ng/mL) | % of cutoff | Total number of Determinations | Dip Card results #Neg/#Pos | Cassette results #Neg/#Pos | Cup results #Neg/#Pos |
| --- | --- | --- | --- | --- | --- |
| 0 | Negative | 30 | 30/0 | 30/0 | 30/0 |
| 75 | 50% | 30 | 30/0 | 30/0 | 30/0 |
| 112.5 | 75% | 30 | 20/10 | 19/11 | 19/11 |
| 187.5 | 125% | 30 | 9/21 | 12/18 | 12/18 |
| 225 | 150% | 30 | 0/30 | 0/30 | 0/30 |
| 300 | 200% | 30 | 0/30 | 0/30 | 0/30 |

{5}

Buprenorphine cutoff 10 ng/mL

| Drug Concentration (ng/mL) | % of cutoff | Total number of Determinations | Dip Card results #Neg/#Pos | Cassette results #Neg/#Pos | Cup results #Neg/#Pos |
| --- | --- | --- | --- | --- | --- |
| 0 | Negative | 30 | 30/0 | 30/0 | 30/0 |
| 5 | 50% | 30 | 30/0 | 30/0 | 30/0 |
| 7.5 | 25% | 30 | 20/10 | 19/11 | 18/12 |
| 12.5 | 125% | 30 | 11/19 | 13/17 | 11/19 |
| 15 | 150% | 30 | 0/30 | 0/30 | 0/30 |
| 20 | 200% | 30 | 0/30 | 0/30 | 0/30 |

b. Linearity/assay reportable range:

Not applicable. This is a qualitative test.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

This device has internal process controls. A colored line appearing in the control region confirms that sufficient sample volume has been applied and that the sample has migrated correctly on the test strip. Users are informed that the test is invalid if a line fails to appear in the control region. External controls are not supplied with this device.

d. Detection limit:

Analytical performance of the device around the cutoff is described in the precision section 1.a above.

e. Analytical specificity:

Cross-reactivity was established by spiking various concentrations of similarly structured drug compounds into drug free urine. The concentration of the drug that produced a response equivalent to the cutoff concentration of the assay was determined. Results are in the tables below:

{6}

Buprenorphine

| Compound | Response equivalent to cutoff (ng/mL) |
| --- | --- |
| Buprenorphine | 10 ng/mL |
| Norbuprenorphine | 15 ng/mL |
| Buprenorphine-3-D-glucuronide | 12.5 ng/mL |
| Norbuprenorphine-3-D-glucuronide | 175 ng/mL |
| Morphine-3-D-glucuronide | 100,000 ng/mL |
| Morphine | >100,000 ng/mL |
| Oxymorphone | >100,000 ng/mL |
| Hydromorphone | >100,000 ng/mL |

Amphetamine

| Compound | Response equivalent to cutoff (ng/mL) |
| --- | --- |
| D-Amphetamine | 300 ng/mL |
| D,L-amphetamine | 850 ng/mL |
| L-Amphetamine | 17,500 ng/mL |
| D-Methamphetamine | 100,000 ng/mL |
| L-Methamphetamine | >100,000 ng/mL |
| (±) 3,4-Methylethyenedioxyamphetamine (MDA) | 650 ng/mL |
| Ephedrine | >100,000 ng/mL |
| 3,4-Methylenedioxyethyamphetamine (MDEA) | >100,000 ng/mL |

Methamphetamine

| Compound | Response equivalent to cutoff (ng/mL) |
| --- | --- |
| (±) Methamphetamine | 1,000 ng/mL |
| (+) Methamphetamine | 500 ng/mL |
| (±) 3,4-Methylenedioxymethamphetamine (MDMA) | 1,000 ng/mL |
| Ranidine (Zantac) | >100,000 ng/mL |
| 3,4-Methylenedioxyamphiteamine (MDA) | >100,000 ng/mL |
| D-Amphetamine | >100,000 ng/mL |
| L-Amphetamine | >100,000 ng/mL |
| Ephedrine | >100,000 ng/mL |

{7}

8
Cocaine

| Compound | Response equivalent to cutoff (ng/mL) |
| --- | --- |
| Cocaine | >100,000 ng/mL |
| Benzoylecogonine | 150 ng/mL |
| Ecgonine HCL | 17,000 ng/mL |

## Unrelated Compounds, Prescription and Over-the-Counter Medication

A 100 µg/mL of various common compounds were added to negative and positive urine samples and assayed. None of the common compounds listed affected the expected results.

| Common Drugs | Ethanol | Biological |
| --- | --- | --- |
| Acetaminophen | Lidocaine | Albumin |
| Acetylsalicylic Acid | Methanol | Bilirubin |
| Amikacin | Oxalic Acid | Creatine |
| Ampicillin | Penicillin-G | Glucose |
| Arterenal | Phenylpropanalamine | Hemoglobin |
| Asprin | Ranitidine | Vitamin (L-Ascorbic Acid) |
| Atropine | Salicyclic Acid | Uric Acid |
| Benzoic Acid | Thioridazine | Urine pH 4.5-9.0 |
| Caffeine | Trifluoperazine | Urine Specific Gravity 1.002-1.035 |

There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results.

## pH and Specific Gravity

To test for possible positive and/or negative interference a negative urine sample and a positive, 50% above the cutoff for each drug urine sample were divided into six aliquots and adjusted to the following pH concentrations 4.5, 5.0, 6.0, 7.0, 8.0 and 9.0. No interference due to pH was observed.

To test for possible positive and/or negative interference from specific gravity, distilled water or sodium chloride was added to negative urine samples or 150% cutoff urine samples to obtain samples having specific gravity of 1.002, 1.020, 1.025, 1.030 and 1.035. No interference due to specific gravity was observed.

{8}

f. Assay cut-off:

BUP 10 ng/mL

AMP 300 ng/mL

mAMP 500 ng/mL

COC 150 ng/mL

Characterization of how the device performs around the claimed cutoff concentration appears in the precision section 1.a, above.

# 2. Comparison studies:

a. Method comparison with predicate device:

Performance was evaluated by 3 operators at one point-of-care site. Each operator tested 80 unaltered clinical samples for each drug on one of three formats. The samples were compared to the GC/MS or LC/MS/MS. The results are presented in the tables below:

Test Card

| Durg ng/mL | Candidate Device Results | Less than half the cutoff concentration by GC/MS or LC/MS/MS | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- | --- |
| BUP (10) | Positive | 0 | 0 | 6 | 32 |
| | Negative | 32 | 8 | 2 | 0 |
| AMP (300) | Positive | 0 | 0 | 6 | 32 |
| | Negative | 32 | 8 | 2 | 0 |
| mAMP (500) | Positive | 0 | 1 | 8 | 32 |
| | Negative | 32 | 7 | 0 | 0 |
| COC (150) | Positive | 0 | 1 | 8 | 32 |
| | Negative | 32 | 7 | 0 | 0 |

{9}

Test Cassette

| Durg ng/mL | Candidate Device Results | Less than half the cutoff concentration by GC/MS or LC/MS/MS | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- | --- |
| BUP (10) | Positive | 0 | 0 | 6 | 32 |
| | Negative | 32 | 8 | 2 | 0 |
| AMP (300) | Positive | 0 | 0 | 6 | 32 |
| | Negative | 32 | 8 | 2 | 0 |
| mAMP (500) | Positive | 0 | 1 | 8 | 32 |
| | Negative | 32 | 7 | 0 | 0 |
| COC (150) | Positive | 0 | 1 | 8 | 32 |
| | Negative | 32 | 7 | 0 | 0 |

Test Cup

| Durg ng/mL | Candidate Device Results | Less than half the cutoff concentration by GC/MS or LC/MS/MS | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- | --- |
| BUP (10) | Positive | 0 | 0 | 7 | 32 |
| | Negative | 32 | 8 | 1 | 0 |
| AMP (300) | Positive | 0 | 0 | 6 | 32 |
| | Negative | 32 | 8 | 2 | 0 |
| mAMP (500) | Positive | 0 | 1 | 8 | 32 |
| | Negative | 32 | 7 | 0 | 0 |
| COC (150) | Positive | 0 | 1 | 8 | 32 |
| | Negative | 32 | 7 | 0 | 0 |

b. Matrix comparison:

Not applicable. The assay is intended for use with urine samples only

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable.

{10}

b. Clinical specificity:
Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.

4. Clinical cut-off:
Not applicable.

5. Expected values/Reference range:
Not applicable.

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

11